论文部分内容阅读
目的:对比分析静脉联合腹腔热灌注化疗与全身静脉化疗治疗老年复发卵巢癌的临床效果。方法:以2010年1月至2010年12月我院收治的80例老年复发卵巢癌患者为研究对象,行随机数字表法均分为观察组和对照组。观察组(n=40)行静脉联合腹腔热灌注化疗对照组(n=40)仅行全身静脉化疗。持续四个周期后统计疗效、不良反应,治疗前后CD3~+、CD4~+、CD4~+/CD8~+;持续随访,统计1年生存率、2年生存率、3年生存率、平均生存时间。结果觌察组总有效率(75.0%vs 52.5%)显著高于对照组;不良反应发生率(22.5%vs 80.0%)明显低于对照组;CD3~+、CD4~+、CD4~+/CD8~+均显著高于对照组;1年生存率(72.5%vs 55.0%)、2年生存率(27.5%vs 7.5%)均显著高于对照组;平均生存时间(16.8±2.1)月vs(13.8±1.8)月显著长于对照组。结论:静脉联合腹腔热灌注化疗治疗老年复发卵巢癌疗效显著,值得推广。
Objective: To compare and analyze the clinical effect of intravenous combined intraperitoneal hyperthermic chemotherapy and systemic vein chemotherapy in the treatment of elderly recurrent ovarian cancer. Methods: From January 2010 to December 2010 in our hospital 80 cases of patients with recurrent ovarian cancer as the research object, random number table were divided into observation group and control group. The observation group (n = 40) received intravenous chemotherapy combined with intraperitoneal hyperthermic perfusion chemotherapy (n = 40). The patients were followed up for four weeks. The patients were followed up for statistical analysis of the efficacy, adverse reactions and CD3 ~ +, CD4 ~ +, CD4 ~ + / CD8 ~ + before and after treatment. The 1-year survival rate, 2-year survival rate, 3-year survival rate and mean survival time. Results The total effective rate (75.0% vs 52.5%) in the observation group was significantly higher than that in the control group. The incidence of adverse reactions (22.5% vs 80.0%) in the observation group was significantly lower than that in the control group. CD3 +, CD4 +, CD4 + / CD8 ~ (+) Were significantly higher than those in the control group. The 1-year survival rate (72.5% vs 55.0%) and 2-year survival rate (27.5% vs 7.5% 13.8 ± 1.8) month was significantly longer than the control group. Conclusion: The combination of intravenous and intraperitoneal hyperthermic perfusion chemotherapy for the treatment of senile recurrent ovarian cancer is significant and worthy of promotion.